INNOPRAN XL Rx
Generic Name and Formulations:
Propranolol HCl 80mg, 120mg; ext-rel caps.
Indications for INNOPRAN XL:
≥18yrs: Take once daily at bedtime (10PM). Take consistently with regard to food. Initially 80mg/day, may increase to 120mg/day.
<18yrs: not recommended.
Cardiogenic shock. Sinus bradycardia, sick sinus syndrome and >1st -degree AV block unless paced. Asthma.
Cardiac ischemia after abrupt discontinuation.
Risk of cardiac ischemia after abrupt discontinuation. Bronchospastic disease. Heart failure. Cardiogenic shock. Wolff-Parkinson-White syndrome. Diabetes. May mask signs of hypoglycemia, hyperthyroidism. Surgery. SLE. Musculoskeletal disease. Renal or hepatic impairment. Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
Potentiated by substrates or inhibitors of CYP2D6 (eg, amiodarone, cimetidine, fluoxetine, paroxetine, quinidine, ritonavir), CYP1A2 (eg, imipramine, ciprofloxacin, theophylline, zolmitriptan), or CYP2C19 (eg, fluconazole), CNS depressants, other antihypertensives, antithyroid drugs, haloperidol, MAOIs, tricyclic antidepressants, alcohol. Antagonized by NSAIDs, aluminum hydroxide; bile acid resins (eg, cholestyramine, colestipol); smoking, chronic alcohol use, and other inducers of CYP2D6, 1A2, or 2C19. Potentiates amiodarone, chlorpromazine, diazepam, lidocaine, bupivacaine, mepivacaine, propafenone, theophylline, thioridazine, warfarin, rizatriptan, zolmitriptan. May increase cardiac effects of calcium channel blockers, digitalis, disopyramide, lidocaine. Bradycardia with catecholamine-depleting drugs. Increased orthostatic hypotension with α-blockers. Caution when withdrawing clonidine. Increased bronchial hyperreactivity with ACEIs. May interfere with glaucoma or thyroid tests. May block epinephrine.
Fatigue, dizziness, constipation, bradycardia, heart failure/block, GI upset, bronchospasm, agranulocytosis, myopathy, myotonia, skin reactions (eg, rash, Stevens-Johnson syndrome, urticaria); rare: SLE, alopecia, impotence.
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis